Dec 112013

The Hygiology Post ®  is presenting information about a company that seems to have much potential to help many people. Both 2012 and 2013 appear to be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site. As a matter of disclosure : The author continues to be a current shareholder in the company.

A recent article on the Senesco Technologies web site (; obtained on 12-10-13) began the following way:



Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial.  More Robust Effects Observed

BRIDGEWATER, N.J. (December 9, 2013) – Senesco Technologies, Inc. (‘Senesco’ or the ‘Company’) (OTC QB: SNTI) reported results of cohort 3 in its Phase 1b/2a clinical study of SNS01-T at the 55th American Society of Hematology Annual Meeting in New Orleans.

Four heavily pre-treated, relapsed or refractory patients, two with diffuse large B-cell lymphoma (DLBCL) and two with multiple myeloma, who were enrolled in cohort 3 at a dosage of 0.2 mg/Kg, completed treatment.  Three of the four patients were evaluable for safety.  One patient had a dose reduction to 0.05 mg/kg due to pre-existing thrombocytopenia and was not evaluable for safety.  No dose-limiting toxicities have been observed in any of the first three cohorts. As previously reported, based upon review of three patients treated at 0.2 mg/kg the Data Review Committee recommended dose escalation to the 4th dose level (0.375 mg/kg) and continued enrollment.

‘In addition to the absence of dose-limiting toxicity, since all patients in cohort 3 completed the full protocol-specified 6-week treatment period, we appear to be seeing  longer treatment durations and fewer dropouts compared to cohorts 1 and 2,’ stated Alice S. Bexon, M.D., Vice President of Clinical Development.  The most frequent adverse events are manageable infusion reactions, which decrease with repeated treatments and platelet count decreases, which recover over time. One myeloma patient had reductions in disease-related proteins in his blood and a second patient with DLBCL had evidence of tumor shrinkage in some lesions.’

Like the previous treatment group, all four patients included at this dose level were refractory to, or had relapsed on, a significant number of previous treatments.  Upon treatment with SNS01-T, three of the four patients exhibited stable disease at week 3 and two of the four were stable at week 6, the end of treatment.

‘The safety profile continues to be a positive feature of SNS01-T in this study,” stated Leslie J. Browne, Ph.D., President and Chief Executive Officer of Senesco. “Since our preclinical data in myeloma and lymphoma demonstrated significant tumor shrinkage at 0.375 mg/kg of SNS01-T, with a p-value of <0.01, we will be looking for evidence of clinical activity at this dose level in cohort 4.’ ”


The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.


Louis DeCola, Jr.  © 2013                                    The Hygiology Post ®